DRMAW
Dermata Therapeutics, Inc.
Set alert
- YTD
- -96.81%
- 1 year
- -96.81%
- Open
- 0.0229
- Prev close
- 0.0012
- Mkt cap
- 409
- Vol
- 146.06K
- Avg vol
- 0
- EPS
- -2.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0005
- High
- 0.0011
- Forward P/E
- 0.00
- Beta
- 0.79
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -2.16
- Beta
- 0.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.24M
- Total cash
- 4.95M
- Total debt
- 0
- Return on equity
- -173.01%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dermatarx.com
News
- Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
- Dermata Therapeutics Announces Private Placement Up To $12.4M
- A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
- Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
- Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks
Your note
Sign in to keep a note on DRMAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Boothbay Fund Management, LLC | 0.64% | 12,000 | 176 | Sep 29, 2024 |
| UBS Group AG | 0.23% | 4,242 | 62 | Sep 29, 2024 |
| Bank of America Corporation | 0.01% | 100 | 1 | Sep 29, 2024 |